Bio-Rad Laboratories B (BIOb)
Bio-Rad Laboratories B is the common stock of Bio-Rad Laboratories, Inc., a healthcare company focused on life science research and clinical diagnostics. Through its Life Science segment, the company develops and distributes instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials such as cells, proteins, and nucleic acids. These products support research, biopharmaceutical manufacturing, quality control, food safety, and science education. Its Clinical Diagnostics segment provides diagnostic test systems, informatics platforms, test kits, quality controls, and related software for clinical, hospital, reference, transfusion, and physician office laboratories. Bio-Rad sells through its direct commercial organization and a network of distributors, agents, brokers, and resellers. Founded in 1952, the company is headquartered in Hercules, California, and operates across the United States, Europe, Asia, Canada, Latin America, and other international markets.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-BIO.B
|
$347.76
|
12.4% Upside
|
Fair
|
—
|
—
|
—
|
Good
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
47.0x
|
1.2x
|
3.1x
|
8.117 B
|
2.442 B
|
14.5%
|
78.1%
|
3.5
|
—
|
211.6%
|